Q1 Earnings Forecast for VNDA Issued By HC Wainwright

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a report released on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS and Q4 2026 earnings at $0.14 EPS.

Separately, StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Trading Up 0.9 %

VNDA opened at $4.46 on Wednesday. The business’s 50-day moving average price is $4.61 and its 200-day moving average price is $4.84. Vanda Pharmaceuticals has a 12 month low of $3.71 and a 12 month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its holdings in shares of Vanda Pharmaceuticals by 186.4% during the 4th quarter. Squarepoint Ops LLC now owns 71,131 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 46,293 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Vanda Pharmaceuticals by 11.2% during the 4th quarter. Two Sigma Advisers LP now owns 156,300 shares of the biopharmaceutical company’s stock valued at $749,000 after purchasing an additional 15,700 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Vanda Pharmaceuticals by 94.7% during the 4th quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 97,017 shares during the last quarter. Stonepine Capital Management LLC bought a new position in shares of Vanda Pharmaceuticals during the 4th quarter valued at about $120,000. Finally, ProShare Advisors LLC boosted its holdings in shares of Vanda Pharmaceuticals by 32.4% during the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 4,599 shares during the last quarter. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.